{"filing":{"accession_number":"0001104659-26-065214","cik":"0001566044","ticker":"VYNE","company_name":"VYNE Therapeutics Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"tm2615387d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926065214/tm2615387d1_8k.htm"},"events":[{"id":9342,"run_id":8195,"accession_number":"0001104659-26-065214","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"The filing discloses a \"proposed transaction between VYNE and Yarrow\" with an S-4 registration statement (File No. 333-294804) filed with the SEC, indicating a material merger or acquisition. The disclosure of an investor presentation by Yarrow Bioscience in connection with this transaction, combined with explicit references to proxy solicitation materials and stockholder voting, confirms this is M\u0026A activity requiring 8-K disclosure under Item 1.01 or related provisions.","company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":947,"accession_number":"0001104659-26-065214","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The filing discloses a \"proposed transaction between VYNE and Yarrow\" with an S-4 registration statement (File No. 333-294804) filed with the SEC, indicating a material merger or acquisition. The disclosure of an investor presentation by Yarrow Bioscience in connection with this transaction, combined with explicit references to proxy solicitation materials and stockholder voting, confirms this is M\u0026A activity requiring 8-K disclosure under Item 1.01 or related provisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:33:38.676015+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":947,"accession_number":"0001104659-26-065214","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The filing discloses a \"proposed transaction between VYNE and Yarrow\" with an S-4 registration statement (File No. 333-294804) filed with the SEC, indicating a material merger or acquisition. The disclosure of an investor presentation by Yarrow Bioscience in connection with this transaction, combined with explicit references to proxy solicitation materials and stockholder voting, confirms this is M\u0026A activity requiring 8-K disclosure under Item 1.01 or related provisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:33:38.676015+00:00","company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","filing_date":"2026-05-21"}]}